Abstract:Funding Acknowledgements Type of funding sources: Public grant(s) – EU funding. Main funding source(s): FCT, Portuguese Foundation for Science and Technology Introduction Cardiac fibrosis is a maladaptive remodelling process of the myocardium, which results from an over-activation of cardiac fibroblasts into myofibroblasts, excessive deposition of extracellular matrix proteins (particularly collagen) and scar formation, ultimately leading to stiffening of the heart wall and greatly compromising heart function. A deeper knowledge of the molecular and cellular fibrogenic processes is crucial to identify novel targets for therapeutic interventions aimed at diminishing cardiac fibrosis and preventing/reversing cardiac remodelling. Recent studies have shown that microRNAs control several features of cardiovascular diseases, including cardiac fibrosis. Methods To systematically identify microRNAs that modulate cardiac fibrosis, we performed a series of high-content microscopy functional screenings using a genome-wide library of microRNA mimics (2,588 mature microRNAs). We focused on key phenotypes relevant to cardiac fibrosis, specifically human primary cardiac fibroblast proliferation, myofibroblast differentiation, and deposition of fibrillary collagen under unstimulated and stimulated conditions. Results Using this approach, we identified 134 microRNAs that strongly modulate myofibroblast differentiation (4-fold change), as well as a high number of microRNAs that completely block cardiac fibroblast proliferation (166 microRNAs) or that strongly modulate collagen deposition (4-fold change; 227 and 96 microRNAs in unstimulated and stimulated conditions, respectively). Of note, we observed that myofibroblast differentiation is not a pre-requisite for collagen deposition, and that specific microRNAs can modulate these phenotypes independently. Clustering performed on the global analysis of the phenotypes elicited by each microRNA led to the selection of 92 microRNAs. We confirmed that the phenotypes could be reproduced in human cardiac fibroblasts from different donors and that some of the phenotypes were conserved in fibroblasts isolated from different tissues, including aorta, skin, and lung. Based on these data, we selected 8 microRNAs for detailed mechanistic characterization - seven of these microRNAs strongly block collagen deposition in stimulated conditions, while exhibiting differential effects on cardiac fibroblast differentiation and/or tissue-specific activities, and 1 microRNA increases collagen deposition. Transcriptomic analysis and additional mechanistic studies showed that 3 of these microRNAs target collagen directly, while the others act through alternative mechanisms. Conclusions Overall, our work establishes microRNAs as powerful modulators of multiple processes critical to cardiac fibrosis and offers a unique opportunity for developing different anti-fibrotic approaches based on the differential modulation of these processes by microRNAs.

Abstract 19935: MicroRNA-21 Regulates Transforming Growth Factor Beta-1 Release from Platelets: A Novel Mechanism for the Anti-Fibrotic Effects of MicroRNA-21 Inhibition

Abstract 300: MicroRNA-21 Affects Platelets and Their Releasate: A Novel Mechanism for the Anti-Fibrotic Effects of MicroRNA-21 Inhibition

82 Microrna-21 Regulates Transforming Growth Factor Beta-1 Release from Platelets

Inhibition of profibrotic microRNA-21 affects platelets and their releasate

Upregulation of Mirna-1228-3p Alleviates TGF-β-induced Fibrosis in Renal Tubular Epithelial Cells.

MiroRNA-21 Mediates Myocardial Fibroblasts Paracrine Stimulated by Indoxyl Sulfate in Vitro

Mir-301A-3p Promotes Hepatic Stellate Cells Activation and Liver Fibrogenesis Via Regulating PTEN/PDGFR-β.

MiR-542-3p controls hepatic stellate cell activation and fibrosis via targeting BMP-7.

Abstract 15822: Mir-29 Contributes to Normal Endothelial Function in Healthy Human Resistance Arterioles and Restores Endothelium-Dependent Vasodilation in Type 2 Diabetes

MicroRNAs in Transforming Growth Factor-Beta Signaling Pathway Associated With Fibrosis Involving Different Systems of the Human Body

MicroRNA-34a: A Novel Therapeutic Target in Fibrosis

MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts

miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis.

MicroRNA-378 suppresses myocardial fibrosis through a paracrine mechanism at the early stage of cardiac hypertrophy following mechanical stress.

MicroRNA-mediated control of cardiac fibrosis: unraveling key players and mechanisms through functional genomics screenings

MicroRNA-221/222 Family Counteracts Myocardial Fibrosis in Pressure Overload-Induced Heart Failure.

Angiotensin II Receptor Blocker Valsartan Ameliorates Cardiac Fibrosis Partly by Inhibiting Mir-21 Expression in Diabetic Nephropathy Mice

A tangled tale of microRNA and cardiac fibrosis

MicroRNA-24-3p alleviates cardiac fibrosis by suppressing cardiac fibroblasts mitophagy via downregulating PHB2

Fibroblast growth factor-21 as a novel metabolic factor for regulating thrombotic homeostasis

Abstract P3023: The Regulatory Role Of Mir-21 In Heart Failure With Preserved Ejection Fraction (hfpef)